Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Quoted FDA Policy

QUOTED. Aug. 30, 2018. Scott Whitaker.

  • News

Executive Summary

AdvaMed CEO Scott Whitaker isn't happy about new Netflix documentary "The Bleeding Edge," which is highly critical of the medical device industry and US FDA. See what Whitaker – who was featured in the film – said about it here.

"I've been in this town a long time [and] I don't believe serious policymakers are going to look at a film like this and make policy and regulatory judgments based on what they said. Because people in this town are smart enough to know that it was an entertainment piece, that it was not fact-based, that it distorted quotes that not only I made but others made, and as a result of that it's not a basis for changing the regulatory process, that by and large has worked very, very well." –Scott Whitaker, CEO, AdvaMed

Click here for a free trial of Medtech Insight

 
Table

View full table

Related Content

Medtech Insight

Topics

Tags:
Quoted FDA Policy
Latest Headlines

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

See All
UsernamePublicRestriction

Register

MT123197

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By